Intercept Pharmaceuticals Inc (ICPT)
19.00
0.00 (0.00%)
USD |
NASDAQ |
Nov 14, 16:00
Price Chart
Key Stats
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 3.116 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 92.81% |
Profile
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. |
URL | https://www.interceptpharma.com |
Investor Relations URL | https://ir.interceptpharma.com/ |
HQ State/Province | New Jersey |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 01, 2024 (est.) |
Last Earnings Release | Nov. 06, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. |
URL | https://www.interceptpharma.com |
Investor Relations URL | https://ir.interceptpharma.com/ |
HQ State/Province | New Jersey |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 01, 2024 (est.) |
Last Earnings Release | Nov. 06, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |